A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden

Author: Fredrikson Sten  

Publisher: Informa Healthcare

ISSN: 1369-6998

Source: Journal of Medical Economics, Vol.16, Iss.6, 2013-06, pp. : 756-762

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content